Spondyloarthritis & psoriatic arthritis
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study
Authors' conclusion
Efficacy of upadacitinib was maintained up to 152 weeks of treatment in this highly treatment-refractory population of patients with PsA. The long-term safety profile of upadacitinib 15 mg was consistent with its known safety profile across indications; no new safety signals were identified.
Study context
- Population
- Patients with PsA and inadequate response (IR) to biologic disease-modifying anti-rheumatic drugs (bDMARDs)entered open-label extension (OLE)
- Participants
- 450 patients
- Comparison
- Upadacitinib 15 mg vs 30 mg QD
- Primary endpoint
- Long-term safety and efficacy
- Follow-up
- Up to 152 weeks
Methodological detailsblinded randomised period, placebo-controlled for 24 weeks, TNFi-IR subanalysis
- Blinded randomised period
- Placebo-controlled for 24 weeks
- TNFi-IR subanalysis
Primary result
As reported in the abstract
Efficacy (ACR20/50/70, MDA, PASI 75/90/100) · week 152
- Improvements observed at week 56 were maintained through week 152
Further findings
Efficacy in TNFi-IR subgroup
- Similar to those reported in the overall population
Safety
Long-term safety · up to 152 weeks
- Well tolerated; no cumulative adverse effects observed through 152 weeks
Original publication
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol. Published 23 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →